Latest News on NBIX

Financial News Based On Company


Advertisement
Advertisement

Neurocrine Biosciences director Gary Lyons sells $2.47M in shares

https://www.investing.com/news/insider-trading-news/neurocrine-biosciences-director-gary-lyons-sells-247m-in-shares-93CH-5040085
Gary A. Lyons, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold 15,000 shares for approximately $2.47 million after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan adopted in August 2026. The sales occurred at prices ranging from $162.45 to $166.06 per share, while the stock currently trades below these prices, with InvestingPro analysis suggesting it is undervalued.

Form 4 Neurocrine Biosciences Inc: Gary A. Lyons (Director) For: 17 November

https://ca.investing.com/news/stock-market-news/form-4-neurocrine-biosciences-inc-gary-a-lyons-director-for-17-november-93CH-4970794
This article reports on a Form 4 filing for Neurocrine Biosciences Inc, detailing a transaction by Director Gary A. Lyons on November 17. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by an insider. The article highlights the company's stock symbol NBIX, which experienced a -3.85% change.

Neurocrine Biosciences (NBIX) Heads To Jefferies With INGREZZA Narrative Keeping Valuation In Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-heads-to-jefferies-with-ingrezza
Neurocrine Biosciences (NBIX) is set to present at the Jefferies Global Healthcare Conference after releasing new data on its tardive dyskinesia drug, INGREZZA. Despite recent share price gains, the company is considered undervalued by analysts, with a fair value estimate of $206.81 against its current trading price of $165.92. The valuation hinges on the success of INGREZZA, CRENESSITY, and its late-stage CNS pipeline, though potential risks like Medicare pricing pressures and VYKAT XR safety concerns remain.

Morgan Stanley maintains Neurocrine Biosciences at Equal-Weight, raises price target to $191 from $185

https://www.tradingview.com/news/tradingview:b5e0feb947df0:0-morgan-stanley-maintains-neurocrine-biosciences-at-equal-weight-raises-price-target-to-191-from-185/
Morgan Stanley has reiterated its "Equal-Weight" rating for Neurocrine Biosciences (NBIX) and increased its price target from $185 to $191, representing a 3.2% rise. This new target suggests a 12.8% upside from the stock's closing price on November 12. Other analysts have recently issued "Buy" or "Outperform" ratings with price targets ranging from $185 to $224.

Neurocrine Biosciences Shares Rose Even As Profit Fell

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-shares-rose-even-as-profit-fell
Neurocrine Biosciences' shares have returned 20.5% in 2026, despite a significant drop in net margin from 26.4% to 18.4% due to higher revenue but flat net income. The company's Q3 2026 revenue increased to US$1.12 billion, supported by INGREZZA, CRENESSITY, and the acquisition of VYKAT XR from Soleno Therapeutics. The current stock price of US$169 reflects a multi-drug story, but the analyst consensus on Simply Wall St suggests it may still be undervalued, assuming strong future pipeline execution and success in obesity projects.
Advertisement

Neurocrine Biosciences, Inc. (NBIX) latest stock news and headlines

https://uk.finance.yahoo.com/quote/NBIX/news/
This article provides the latest news and headlines for Neurocrine Biosciences, Inc. (NBIX), including recent press releases, SEC filings, and analyst opinions. It also details the company's stock performance with trailing total returns compared to the S&P 500. Key updates include presentations at healthcare conferences, new survey results for INGREZZA®, and the initiation of a Phase 2 Alzheimer's study.

Is Ingrezza Quality Of Life Data Altering The Investment Case For Neurocrine Biosciences (NBIX)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/is-ingrezza-quality-of-life-data-altering-the-investment-cas
Neurocrine Biosciences recently reported new data for INGREZZA, showing that patients with tardive dyskinesia experienced fewer work and school disruptions and improved quality of life. While this data strengthens INGREZZA's clinical story and could support sales amidst pricing pressures, it doesn't immediately alter the investment narrative, which still faces near-term challenges from Medicare pricing, VYKAT XR safety scrutiny, and the performance of its late-stage psychiatry pipeline. The company's strong Q3 2026 results, heavily reliant on INGREZZA, underscore the importance of these patient-reported benefits for sustained revenue growth towards analyst targets of $5.1 billion by 2029.

Form 144 NEUROCRINE BIOSCIENCES For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-neurocrine-biosciences-for-10-november-93CH-4948145
This article reports on the filing of Form 144 for Neurocrine Biosciences (NBIX) on November 10, 2026. Form 144 indicates an insider's intent to sell restricted or controlled securities. The article provides the title and date of the filing, along with a link to view comments.

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-2026-jefferies-global-healthcare-conference-302935443.html
Neurocrine Biosciences, Inc. announced its executives will participate in the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026, at 3:30 p.m. Greenwich Mean Time. A webcast of the presentation will be available on the company's investor relations website, with a replay archived for approximately one month. Neurocrine Biosciences is a biopharmaceutical company focused on treatments for neurological, psychiatric, endocrine, and immunological disorders.

Is Neurocrine Biosciences (NBIX) Still Cheap As INGREZZA Data And Earnings Outlook Lift Sentiment?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/is-neurocrine-biosciences-nbix-still-cheap-as-ingrezza-data
Neurocrine Biosciences (NBIX) has seen positive momentum with a 16.17% 7-day share price return and an 18.55% 30-day return, driven by fresh INGREZZA patient outcome data and a strengthened earnings outlook. Despite recent gains, Simply Wall St's analyst consensus views the stock as 18% undervalued, with a fair value of $206.81 per share compared to its last close of $168.86. However, potential risks include tougher INGREZZA pricing and reimbursement challenges, as well as VYKAT XR safety or uptake setbacks.
Advertisement

The Strong Earnings Posted By Neurocrine Biosciences (NASDAQ:NBIX) Are A Good Indication Of The Strength Of The Business

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/the-strong-earnings-posted-by-neurocrine-biosciences-nasdaqn
Neurocrine Biosciences recently reported strong earnings, which were positively received by the market. Further analysis reveals encouraging factors for investors, such as a negative accrual ratio of -0.13, indicating strong cash conversion with free cash flow significantly exceeding statutory profit. The company's profit was also impacted by unusual items worth US$122m, which contributed to high cash conversion, suggesting that underlying earnings power may be better than statutory numbers appear.

Adults with uncontrollable movements averaged 5.6 missed work or school days a month before treatment, versus 2.0 after.

https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-presents-new-tardive-dyskinesia-survey-n8emh1h8v4bl.html
Neurocrine Biosciences announced new survey results showing that adults with tardive dyskinesia (TD) experienced significantly fewer work and school disruptions after starting treatment with INGREZZA. Reported disruptions fell from 57% to 21%, and average missed work/school days decreased from 5.6 to 2.0 per month. A separate analysis of the KINECT-PRO study also demonstrated clinically meaningful patient-reported improvements in various physical and socio-emotional aspects of TD with INGREZZA treatment.

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-tardive-dyskinesia-survey-results-showing-fewer-work-and-school-disruptions-with-ingrezza-valbenazine-capsules-302930000.html
Neurocrine Biosciences announced new survey results showing that adults with tardive dyskinesia (TD) experienced fewer disruptions to work and school, and reduced self-consciousness after starting treatment with INGREZZA (valbenazine) capsules. A separate analysis of the KINECT-PRO™ study also revealed significant patient-reported improvements across physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™). These findings highlight INGREZZA's effectiveness not only in reducing involuntary movements but also in improving patients' daily functioning and quality of life.

Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-11-04

https://seekingalpha.com/article/4961972-neurocrine-biosciences-inc-2026-q3-results-earnings-call-presentation
Neurocrine Biosciences, Inc. published their slide deck in conjunction with their 2026 Q3 earnings call. The company reported an EPS of $3.29, beating estimates by $0.54, and revenue of $1.12 billion, a 41.24% year-over-year increase, beating estimates by $78.98 million.

Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.27, Implies 44% Upside

https://www.tradingview.com/news/tradingview:f537e4219963c:0-neurocrine-biosciences-inc-stock-12-month-price-target-raised-to-209-27-implies-44-upside/
The average 12-month price target for Neurocrine Biosciences, Inc. (NBIX) stock has increased to $209.27 from $207.37, based on estimates from 28 analysts. This updated target suggests a potential upside of approximately 44% from the Nov. 2 closing price. The consensus analyst rating for NBIX remains a "Buy" across 31 covering analysts.
Advertisement

Neurocrine stock rises on Q3 beat, guidance hike (NBIX:NASDAQ)

https://seekingalpha.com/news/4663955-neurocrine-stock-rises-q3-beat-guidance-hike
Neurocrine Biosciences (NBIX) experienced a significant intraday stock jump of over 15% after reporting strong Q3 2026 results. The rare disease drugmaker exceeded quarterly expectations and raised its guidance, with revenue reaching $1.1 billion, representing approximately 41% year-over-year growth. This performance marks the company's largest intraday gain in six years.

Neurocrine defends Prader-Willi drug after another patient death

https://www.biospace.com/business/neurocrine-defends-prader-willi-drug-after-another-patient-death
Neurocrine Biosciences is facing scrutiny over the safety of its Prader-Willi syndrome drug, Vykat, after another patient death brought the total reported deaths to eight. The company, which acquired the drug with Soleno Therapeutics in April, confirmed the latest death but reiterated confidence in Vykat's benefit-risk profile, attributing serious incidents to patients with complex medical issues. Neurocrine plans a new study in 2027 to explore dosing and safety for these vulnerable patients, aiming to restore confidence and growth for the drug.

Neurocrine Biosciences (NASDAQ:NBIX) Q3 Earnings Beat as INGREZZA Guidance Raised

https://www.chartmill.com/news/NBIX/Chartmill-57515-Neurocrine-Biosciences-NASDAQNBIX-Q3-Earnings-Beat-as-INGREZZA-Guidance-Raised
Neurocrine Biosciences (NASDAQ:NBIX) reported strong third-quarter 2026 results, surpassing analyst expectations for both revenue and non-GAAP EPS. The company also raised its full-year 2026 net sales guidance for its key product, INGREZZA, which led to a positive after-market reaction for the stock. While INGREZZA remains the primary revenue driver, potential risks include product concentration and standard biopharma pipeline developments.

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

https://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-q3-earnings-231005118.html
Neurocrine Biosciences (NBIX) reported strong Q3 2026 earnings of $3.29 per share, significantly beating the Zacks Consensus Estimate of $2.54, and revenues of $1.12 billion, surpassing estimates by 8.12%. The company has consistently topped both EPS and revenue estimates over the past year, indicating robust financial performance. Despite outperforming expectations, NBIX shares have underperformed the S&P 500 year-to-date, prompting investor focus on future earnings outlook and management commentary.

Neurocrine Biosciences (NBIX) Earnings Put Its Valuation Back In Focus

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-earnings-put-its-valuation-back/amp
Neurocrine Biosciences (NBIX) is gaining attention after its Q3 2026 results showed revenue of US$1.12 billion and net income near US$206.5 million. Despite a recent share price pullback, the company is considered 29.7% undervalued with a fair value of $206.81, against its current trading price of $145.35. The expansion of its commercial portfolio beyond INGREZZA, including CRENESSITY and VYKAT XR, is diversifying revenue and improving margin resilience.
Advertisement

Neurocrine Biosciences Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:719376:0-neurocrine-biosciences-q3-2026-earnings-call-is-live/
Neurocrine Biosciences' (NBIX) quarterly earnings call has commenced, where executives are discussing the latest financial results. This call provides an opportunity for management to elaborate on the company's performance, potentially offering insights into future demand, margins, or capital spending that could influence market sentiment.

Form 144 NEUROCRINE BIOSCIENCES For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-neurocrine-biosciences-for-2-november-93CH-4923443
This article announces a Form 144 filing for Neurocrine Biosciences (NBIX) on November 2nd. It notes a 3.67% increase for NBIX and includes standard market data and related news without further details on the filing itself.

Form 144 NEUROCRINE BIOSCIENCES For: 31 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-neurocrine-biosciences-for-31-october-93CH-4947003
This article announces the filing of Form 144 for Neurocrine Biosciences on October 31. It provides a brief financial update related to the company, indicating a slight decrease in its stock. The piece is a concise notification about a regulatory filing relevant to investors.

A director, George Morrow, proposes selling 300 Neurocrine Biosciences (NBIX) shares.

https://www.stocktitan.net/sec-filings/NBIX/144-neurocrine-biosciences-inc-sec-filing-be028ff7f319.html
Neurocrine Biosciences director George Morrow has filed a notice to sell 300 common shares of NBIX, acquired through the exercise of stock options, with an approximate sale date of October 30, 2026. The proposed sale has an aggregate market value of $43,914 and names Morgan Stanley Smith Barney LLC as the broker. This transaction is governed by Rule 144, which outlines conditions for insiders to sell restricted shares.

Neurocrine Biosciences stock: Q3 results set for November 2

https://www.ad-hoc-news.de/boerse/news/nebenwerte/neurocrine-biosciences-stock-q3-results-set-for-november-2/70431480
Neurocrine Biosciences is scheduled to release its third-quarter 2026 financial results on November 2, 2026, at 4:00 p.m. Eastern Time, followed by a conference call. The company, which focuses on neurological, psychiatric, endocrine, and immunological disorders, will provide an update on its commercial performance and outlook. Investors will be keen to assess demand, product execution, and the company's development pipeline.
Advertisement

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

https://www.prnewswire.com/news-releases/neurocrine-biosciences-launches-interactive-educational-resources-to-support-clinical-learning-in-classic-congenital-adrenal-hyperplasia-302924268.html
Neurocrine Biosciences has launched new interactive educational resources, "bootCAHmp" and "DiscoverCAH," to enhance healthcare providers' understanding and management of classic congenital adrenal hyperplasia (CAH). These resources offer evidence-based education and virtual patient case experiences, developed in collaboration with leading endocrinologists, to help clinicians deepen their knowledge of this rare genetic condition and its treatment challenges, including the use of CRENESSITY® (crinecerfont). The aim is to equip clinicians to better recognize, manage, and navigate the complexities of CAH.

Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation

https://www.chartmill.com/news/NBIX/Chartmill-57069-Neurocrine-Biosciences-NASDAQNBIX-Affordable-Growth-at-a-Reasonable-Valuation
Neurocrine Biosciences (NASDAQ:NBIX) is identified as an "Affordable Growth" stock due to its strong performance across growth, valuation, profitability, and health ratings. The company exhibits robust EPS and revenue growth, a reasonable valuation compared to industry peers, solid profitability with high margins, and a healthy, debt-free balance sheet. While some risks like margin pressure and share dilution exist, these are considered manageable for a growth-oriented investment.

Healthcare stocks with strong revenue growth and attractive valuations

https://www.tradingview.com/news/seekingalpha:bf47d7c46094b:0-healthcare-stocks-with-strong-revenue-growth-and-attractive-valuations/
This article identifies healthcare stocks that exhibit strong year-over-year revenue growth alongside attractive valuations, as rated by Seeking Alpha Quant Valuation Grades. The list features nine companies across biopharmaceuticals, specialty pharmaceuticals, healthcare services, and biotechnology, with Harmony Biosciences, Ironwood Pharmaceuticals, and CorMedix among the top performers in revenue growth and valuation. Investors are advised to consider additional factors like profitability and regulatory risks beyond just growth and valuation grades.

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-analysis-establishing-benchmark-for-clinically-meaningful-change-in-overall-health-reported-by-patients-with-tardive-dyskinesia-302918146.html
Neurocrine Biosciences announced new research establishing a 6-point increase on the EQ Visual Analogue Scale (EQ-VAS) as a clinically meaningful change in overall health for patients with tardive dyskinesia (TD) treated with INGREZZA. This benchmark provides context for the mean 13.1-point improvement observed in the KINECT-PRO™ study and complements existing measures of TD impact and movement severity. These findings, along with two other analyses, are being presented at the Academy of Managed Care Pharmacy Nexus 2026 conference.

Neurocrine's 23% Slide Puts Ingrezza Raise And Crenessity Ramp Under The Microscope

https://finviz.com/news/407954/neurocrines-23-slide-puts-ingrezza-raise-and-crenessity-ramp-under-the-microscope
Neurocrine Biosciences is facing scrutiny as its stock has fallen 22.6% despite raising Ingrezza guidance, posting record revenue, and expanding its commercial franchises. Ahead of its third-quarter report on November 2, investors are questioning whether the operational performance is weakening or if the market has simply stopped valuing its growth. The report will largely hinge on Ingrezza's performance relative to its raised guidance and the continued acceleration of Crenessity sales to validate the company's multi-product thesis.
Advertisement

Expert Backing For VYKAT XR Could Matter For Neurocrine Biosciences Stock

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/expert-backing-for-vykat-xr-could-matter-for-neurocrine-bios
Neurocrine Biosciences' VYKAT XR, an FDA-approved treatment for hyperphagia in Prader-Willi syndrome, has received expert validation, framing hyperphagia as a complex, lifelong neurobiological condition. This expert perspective supports Neurocrine Biosciences' rare disease focus and could enhance VYKAT XR's role in comprehensive PWS management, potentially influencing the company's investment narrative. While this is a positive development for VYKAT XR's medical positioning, the short-term focus remains on INGREZZA's performance amidst Medicare headwinds and the efficient conversion of revenue into cash for reinvestment in CNS and endocrine programs.

Neurocrine Biosciences (NBIX) Could Be 31% Undervalued Following VYKAT XR And Alzheimer’s Trial News

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-could-be-31-undervalued-followin/amp
Neurocrine Biosciences (NBIX) is attracting attention due to expert perspectives on VYKAT XR for hyperphagia in Prader Willi syndrome and the launch of a Phase 2 Alzheimer’s trial for NBI-1117567. Despite recent mixed share price performance, the company is considered 31% undervalued by analysts, with a fair value estimate of $206.81 against a last close of $142.70. This valuation is based on its expanding commercial portfolio, including INGREZZA, CRENESSITY, and VYKAT XR, which broadens revenue sources and can improve margin resilience.

Neurocrine Biosciences, Inc. Estimates – NASDAQ:NBIX

https://www.tradingview.com/symbols/NASDAQ-NBIX/financials-estimates/
The article provides an overview of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) financials and analyst estimates on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The platform offers tools to visualize trends over time for informed decision-making.

Neurocrine Biosciences, Inc. Estimates – TRADEGATE:NB3

https://www.tradingview.com/symbols/TRADEGATE-NB3/financials-estimates/
This article provides an overview of Neurocrine Biosciences, Inc. (NB3) on the Tradegate Exchange, focusing on its financial estimates. It highlights access to reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates and visualize trends over time.

Price to earnings forward of Neurocrine Biosciences, Inc. – TRADEGATE:NB3

https://www.tradingview.com/symbols/TRADEGATE-NB3/financials-statistics-and-ratios/price-earnings-fwd/
This article provides the "Price to earnings forward" metric for Neurocrine Biosciences, Inc. (TRADEGATE:NB3). It appears to be a financial data point from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet. The content is primarily a listing of financial information rather than an analytical piece.
Advertisement

Neurocrine Biosciences (NBIX) Stock May Be Below Fair Value Following Phase 2 Alzheimer’s Study

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-stock-may-be-below-fair-value-fo/amp
Neurocrine Biosciences (NBIX) stock appears to be trading below its fair value, despite delivering steady long-term gains for shareholders and recent clinical updates. The company's P/E ratio is lower than its broader peer group, suggesting it might be undervalued, especially with the recent launch of VYKAT XR and ongoing Phase 2 Alzheimer's study. Investors may be awaiting more evidence of the impact of these developments on future earnings.

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-in-orphanet-journal-of-rare-diseases-advancing-understanding-of-hyperphagia-in-prader-willi-syndrome-302917274.html
Neurocrine Biosciences announced a publication in Orphanet Journal of Rare Diseases, highlighting hyperphagia in Prader-Willi syndrome (PWS) as a complex, neurobiologically driven condition requiring comprehensive assessment and management. The article emphasizes that hyperphagia is multidimensional, influenced by brain regulation, behavior, and environment, and extends beyond just food intake. Experts conclude that VYKAT® XR (diazoxide choline) extended-release tablets represent a significant advancement in treating hyperphagia in PWS, complementing behavioral and environmental strategies.

Needham keeps Buy target at USD 204.00 for Neurocrine Biosciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/needham-keeps-buy-target-at-usd-204-00-for-neurocrine-biosciences-stock/70376721
Needham has reiterated a Buy rating for Neurocrine Biosciences (NBIX) with a price target of USD 204.00, suggesting a 44.55% upside from its recent Nasdaq price. The company is set to report its third-quarter 2026 results on November 2, 2026, after reporting strong Q2 revenue growth of 39.49% year-over-year. The stock is currently trading above its 52-week low, with a market capitalization of USD 14.4 billion.

Neurocrine Biosciences starts Alzheimer's Phase 2 trial

https://mugglehead.com/neurocrine-biosciences-nbi-567-alzheimers-phase-2-trial/
Neurocrine Biosciences has initiated a Phase 2 trial for NBI-'567, targeting cognitive impairment in 135 Alzheimer's patients. The 12-week placebo-controlled study will test two doses as an add-on to existing treatments, with primary completion estimated for May 2028. The drug is designed to activate M1 and M4 muscarinic receptors involved in learning and memory.

Neurocrine starts phase 2 trial of Alzheimer’s drug candidate By Investing.com

https://ca.investing.com/news/stock-market-news/neurocrine-starts-phase-2-trial-of-alzheimers-drug-candidate-93CH-4890814
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has initiated a Phase 2 clinical study for NBI-1117567, an M1/M4 selective muscarinic agonist, as an adjunctive treatment for mild to moderate Alzheimer's disease. The randomized, double-blind, placebo-controlled trial will involve approximately 135 adults and assess efficacy, safety, tolerability, and pharmacokinetics over a 12-week period. This advancement reflects Neurocrine's commitment to developing new treatment options for the over 7 million Americans living with Alzheimer's.
Advertisement

Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment

https://pluang.com/en/news-feed/neurocrine-biosciences-mulai-uji-klinis-fase-2-nbi-567-pengobatan-alzheimer
Neurocrine Biosciences has initiated a Phase 2 clinical trial for NBI-1117567, an oral drug designed to enhance cognition in adults with mild to moderate Alzheimer's disease by targeting muscarinic receptors. The 12-week study will evaluate the drug's efficacy and safety in approximately 135 patients already receiving acetylcholinesterase inhibitors. This trial aims to explore a new treatment option for cognitive decline, potentially clarifying NBI-1117567's role in managing Alzheimer's symptoms alongside existing therapies.

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

https://www.prnewswire.com/news-releases/neurocrine-biosciences-initiates-phase-2-clinical-study-evaluating-nbi-567-in-adults-with-alzheimers-disease-302913245.html
Neurocrine Biosciences has commenced a Phase 2 clinical study for NBI-'567, an investigational M1/M4 selective muscarinic agonist, for adults with mild to moderate Alzheimer's disease. The drug aims to improve cognitive performance by activating muscarinic receptors involved in learning and memory. This randomized, double-blind, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-'567 as an adjunctive treatment.

How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/how-new-crenessity-data-at-neurocrine-biosciences-stock-has
Neurocrine Biosciences has released new real-world data from its CAHtalyst program for CRENESSITY, showing its effectiveness in managing congenital adrenal hyperplasia in children and adults. While this data supports CRENESSITY's clinical role and Neurocrine's multi-product investment thesis, it doesn't significantly alter the near-term financial outlook. The company's future growth largely depends on INGREZZA's pricing and reimbursement, as well as the success of its broader pipeline.

Needham sets USD 204.00 target for Neurocrine Biosciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/needham-sets-usd-204-00-target-for-neurocrine-biosciences-stock/70349375
Needham has reaffirmed its "Buy" rating for Neurocrine Biosciences (NBIX) and set a price target of USD 204.00, representing a 50.40% upside from its recent closing price of USD 135.71. The company's Q2 2026 revenue was USD 959.00 million, a 39.50% increase year-over-year, and its Q3 2026 financial results are scheduled for release on November 2, 2026.

How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/how-new-crenessity-data-at-neurocrine-biosciences-stock-has/amp
Neurocrine Biosciences released new real-world data from its CAHtalyst program for CRENESSITY, demonstrating its effectiveness in managing classic congenital adrenal hyperplasia in children and adults. This data reinforces CRENESSITY's clinical role and strengthens Neurocrine Biosciences' multi-product investment thesis, which also relies on INGREZZA and CNS assets. Analysts anticipate significant revenue and earnings growth for the company, although potential risks like Medicare pricing headwinds for INGREZZA and execution challenges could impact sentiment.
Advertisement

Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/is-neurocrine-biosciences-nbix-undervalued-on-pipeline-and-p
Neurocrine Biosciences (NBIX) shares are currently trading around $136.95, which is considered an 18% undervaluation compared to a fair value of $166.59. This perceived undervaluation stems from concerns over product concentration, potential pricing pressures on its key drug INGREZZA due to IRA mandates starting in 2029, and the need for its pipeline to drive future growth. Despite recent share price declines, the company has shown solid long-term shareholder returns, and its outlook could improve if revenue momentum continues or if safety concerns for VYKAT XR ease.

Is Neurocrine Biosciences (NBIX) Undervalued On Pipeline And Pricing Risks?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/is-neurocrine-biosciences-nbix-undervalued-on-pipeline-and-p/amp
Neurocrine Biosciences (NBIX) shares are currently trading around $136.95, which is an implied discount to their fair value of $166.59, despite recent mixed returns. The perceived undervaluation is influenced by concerns about product concentration, potential pricing pressure from the IRA, and the pipeline's ability to drive future growth. Investors are weighing these risks against the company's solid revenue and net income figures.

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-real-world-evidence-mapping-the-lifelong-evolving-impact-of-classic-congenital-adrenal-hyperplasia-302910704.html
Neurocrine Biosciences has released new real-world data highlighting the varied and evolving impact of classic congenital adrenal hyperplasia (CAH) throughout a patient's life, from childhood to adulthood. The study, using de-identified electronic medical records from the CAHtalog® registry, demonstrates how clinical needs, treatment management, and day-to-day challenges shift over time. These findings aim to help healthcare professionals better anticipate patient needs and improve education, support strategies, and care coordination for individuals living with CAH.

Needham reiterates Buy rating on Neurocrine Biosciences, $204 price target

https://www.tradingview.com/news/tradingview:fe036ef3f3ff1:0-needham-reiterates-buy-rating-on-neurocrine-biosciences-204-price-target/
Needham has reiterated its Buy rating on Neurocrine Biosciences (NBIX) and maintained a price target of $204.00, suggesting a 49.0% upside from its October 15 close. The positive outlook is driven by the company's strong portfolio of FDA-approved treatments like Ingrezza and Ongentys, as well as its promising and diverse drug pipeline.

RBC keeps USD 187.00 target for Neurocrine Biosciences stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rbc-keeps-usd-187-00-target-for-neurocrine-biosciences-stock/70331778
RBC Capital has maintained its Buy rating and USD 187.00 price target for Neurocrine Biosciences (NBIX). The company is set to release its third-quarter 2026 financial results on November 2, 2026. Neurocrine Biosciences reported strong second-quarter revenues of USD 959.0 million, a 39.50% increase year-over-year.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement